Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI)
Pediatric Nephrology · 2026
DOI: 10.1007/s00467-026-07205-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Nephrology, 2026. Verfasst von Emma C Alexander und 4 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Intensive Care Unit, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK. Hauptthemen laut MEDLINE: Terlipressin, Hepatorenal Syndrome, Acute Kidney Injury, Vasoconstrictor Agents. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Children with chronic liver disease are at increased risk of acute kidney injury (AKI), which could be non-hepatorenal syndrome AKI (non-HRS-AKI) or hepatorenal syndrome AKI (HRS-AKI). Approximately 5–10% of these children develop HRS-AKI. In this cohort, portal hypertension leads to splanchnic vasodilatation, reduced mean arterial pressure, and compensatory renal arteriolar vasoconstriction. The reduction of mean arterial pressure and renal vasoconstriction reduces renal perfusion, causing functional renal failure and AKI (acute kidney injury). HRS-AKI may be precipitated by sepsis or inflammation, which may impact cardiac function in patients with cirrhotic cardiomyopathy. While liver transplantation remains curative, adult randomised controlled trials have demonstrated that treatment with terlipressin can potentially reverse HRS-AKI. Limited paediatric studies also suggest terlipressin may also be effective in children, though effects on mortality remain unexplored. In this review, we explore the prevalence and pathophysiology of HRS-AKI in paediatric liver disease, summarise evidence from adult trials supporting terlipressin use, highlight cautions and contraindications associated with its use in adults and children, and propose principles for its safe prescription. Additionally, we outline future research priorities, including the potential role of renal biomarkers in managing this high-risk population. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paediatric Intensive Care Unit, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK.
- Paediatric Critical Care Research Group, Imperial College London, London, UK.
- UCL Institute for Liver and Digestive Health, Royal Free Campus, London, UK.
- Division of Nephrology and Hypertension, Cincinnati Children's Hospital, Cincinnati, OH, USA.
- Paediatric Intensive Care Unit, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK. akash.deep@nhs.net.
- Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK. akash.deep@nhs.net.
Zitieren
APA
Alexander, E. C., Wyness, B., Moore, K., Flores, F., & Deep, A. (2026). Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI). Pediatric Nephrology. https://doi.org/10.1007/s00467-026-07205-w
Vancouver
Alexander EC, Wyness B, Moore K, Flores F, Deep A. Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI). Pediatric Nephrology. 2026. doi:10.1007/s00467-026-07205-w
BibTeX
@article{Alexander2026,
author = {Alexander, Emma C and Wyness, Benjamin and Moore, Kevin and Flores, Francisco and Deep, Akash},
title = {Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI)},
journal = {Pediatric Nephrology},
year = {2026},
doi = {10.1007/s00467-026-07205-w}
}
EUVIMED